Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chromium pidolate is a trivalent chromium salt of pidolic acid (L-pyroglutamic acid) that serves as a bioavailable source of chromium, an essential trace mineral. It is primarily recognized for its role in enhancing the action of insulin, thereby facilitating the metabolism of carbohydrates, lipids, and proteins. Mechanistically, chromium is thought to increase insulin receptor phosphorylation and promote glucose transporter translocation to the cell membrane. Clinical investigations, such as those involving patients with type 2 diabetes, have evaluated its potential to improve glycemic control and reduce markers of oxidative stress, including thiobarbituric acid reactive substances (TBARS). While widely available as a dietary supplement, its therapeutic efficacy in metabolic disorders continues to be explored in clinical settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chromium pidolate.